ESR1 and breast cancer: To test whether the above-observed risperidone effect on mammary early lesions is broadly applicable across different subtypes of breast cancer, we administered risperidone or vehicle to mice transgenic for MMTV-Wnt1 [50], which develops basal-like tumors and some estrogen receptor (ER)-positive tumors [51–53].